



(51) International Patent Classification:

A61Q 19/00 (2006.01) A61Q 19/08 (2006.01)
A61Q 19/02 (2006.01) A61K 8/97 (2017.01)

(21) International Application Number:

PCT/US2016/064888

(22) International Filing Date:

5 December 2016 (05.12.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/264,604 8 December 2015 (08.12.2015) US

(71) Applicant: **THE PROCTER & GAMBLE COMPANY** [US/US]; One Procter & Gamble Plaza, Cincinnati, Ohio 45202 (US).

(72) Inventors: **OSBORNE, Rosemarie**; One Procter & Gamble Plaza, Cincinnati, Ohio 45202 (US). **MULLINS, Lisa, Ann**; One Procter & Gamble Plaza, Cincinnati, Ohio 45202 (US). **KOGANOV, Michael**; AkzoNobel Surface

Chemistry LLC, 23 Snowden Avenue, Ossining, NY 10562 (US).

(74) Agent: **KREBS, Jay A.**; c/o The Procter & Gamble Company, Global IP Services, One Procter & Gamble Plaza, C9, Cincinnati, Ohio 45202 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,

[Continued on next page]

(54) Title: METHOD OF REGULATING A SKIN CONDITION




Fig. 2

(57) Abstract: A method of regulating a skin conditions that includes applying a safe and effective amount of achachariu to a target portion of skin in need of treatment or where treatment is desired. The achachariu can be in the form of a bioactive ingredient that exhibits anti-inflammatory, anti-oxidant, and/or anti-aging properties, and which is free or substantially free of benzophenones and/or protein. The achachariu ingredient may be a serum fraction and/or an extract, and may be incorporated into a skin care composition formulated for topical use on skin.

WO 2017/100111 A1

TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, **Published:**
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, — *with international search report (Art. 21(3))*
LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

METHOD OF REGULATING A SKIN CONDITION

FIELD

The present invention relates generally to regulating a skin condition with achachariu. More specifically, the present invention relates to using achachariu serum fractions and/or
5 extracts to regulate a skin condition, for example, by incorporating the fraction or extract into a skin care composition.

BACKGROUND

Human skin is constantly subjected to a variety of insults from extrinsic and intrinsic sources. Extrinsic sources include ultraviolet radiation, environmental pollution, wind, heat,
10 infrared radiation, low humidity, harsh surfactants, abrasives, etc, whereas intrinsic sources include chronological aging and other biochemical changes from within the body. Whether extrinsic or intrinsic, these factors can result in visible signs of damage (e.g., fine lines, wrinkling, hyperpigmentation, sallowness, sagging, dark under-eye circles, puffy eyes, enlarged pores, diminished rate of skin cell turnover, flaking, scaling, dryness, roughness). Currently,
15 there are a number of skin care products available to consumers, the majority of which are directed to delaying, minimizing or even reversing the changes associated with aging skin and/or environmental damage to skin. However, there is a continuing need for products and methods that seek to remedy undesirable skin conditions.

One potential source of bioactive ingredients for regulating conditions in mammalian
20 keratinous tissue is achachariu. Achachariu (*Garcinia humilis*) is a plant belonging to the Clusiaceae (or Guttiferae) family and is widely distributed in the region of Santa Cruz, Bolivia. The achachariu plant (e.g., fruit) is used in Bolivian folk medicine for its healing, digestive, and laxative properties. In Brazil, achachariu is popularly known as “achacha” and is used in folk medicine to treat rheumatism, inflammation, pain and gastric disorders (Alves TMA, Silva AF,
25 Brandão M, Grandi TSM, Smânia EF et al. (2000) Biological Screening of Brazilian Medicinal Plants. Mem Inst Oswaldo Cruz 95: 367-373 and Barbosa W, Chagas EA, Martins L, Pio R, Tucci ML et al. (2008) “Germinação de sementes e desenvolvimento inicial de plântulas de achachariu. Rev Bras Frutic.” 30: 263-266).

Some studies suggest that achachar, like many plants, contains unwanted components of
30 concern, such as benzophenones (e.g., guttiferone A) and proteins. See, e.g., Acuña UM, et al., (2009) Polyisoprenylated benzophenones from Clusiaceae: potential drugs and lead compounds. Curr Top Med Chem 9: 1560-1580). Benzophenones are known to exhibit various biological

activities such as cytotoxic, genotoxic antimicrobial, antiviral and antioxidant activity. See, e.g., Terrazas PM, et al. (2013) "Benzophenone guttiferone A from *Garcinia achachairu* Rusby (Clusiaceae) Presents Genotoxic Effects in Different Cells of Mice;" PLoS ONE 8(11): e76485). And proteins are known to cause allergic reactions when contacted with skin. See, e.g., V. Janssens, et al., (2015) "Protein contact dermatitis: myth or reality?" British Journal of Dermatology; 132: 1-6). Thus, in some instances it may be desirable to remove these unwanted components or reduce their concentrations substantially when providing an achachariu ingredient for incorporation into a skin care composition.

SUMMARY OF THE INVENTION

10 Disclosed herein is a method of regulating a skin condition, which comprises identifying a target portion of skin in need of treatment or where treatment is desired; and applying an effective amount of achachariu serum fraction to the target portion of skin during a treatment period, wherein the treatment period is sufficient for the achachariu serum fraction to provide a skin care benefit.

15 Also disclosed is a method of providing skin care benefit, which comprises identifying a target portion of keratinous tissue in need of treatment; and applying an effective amount of an achachariu extract to the target portion of skin during a treatment period, wherein the treatment period is sufficient for the achachariu extract to provide a skin care benefit.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic of a cross-sectional view of an achachariu fruit.

20 FIG. 2 is a schematic of a process for preparing bioactive serum fractions and bioactive fraction extracts derived from achachariu.

FIGS. 3A, 3B, 4A, 4B are graphs illustrating absorbance spectra of achachariu serum fractions and extracts.

DETAILED DESCRIPTION OF THE INVENTION

25 It has now been discovered that achachariu (*Garcinia humilis*), especially bioactive extracts and serum fractions obtained from particular portions of the achachariu plant, possess properties that may be beneficial for regulating certain skin conditions. In particular, bioactive achachariu fruit extracts and serum fractions exhibit surprising properties related to anti-oxidation, inhibiting melanin production, and inhibiting lipogenesis, which can be exploited to
30 provide a wide variety of different skin health benefits. Thus, it is now possible to regulate a

particular skin condition by applying an effective amount of achachariu to a target portion of skin where treatment is needed or desired.

It may also be desirable to provide achachariu serum fractions and/or extracts that are free or substantially free of benzophenones (e.g., guttiferone A) and/or proteins. As used
5 herein, “substantially free of proteins” means less than 0.15% total protein content determined by hydrolyzed and un-hydrolyzed amino acid analysis conducted on an Hitachi L-8900 amino acid analyzer or equivalent, and “substantially free of benzophenones” means less than 0.1% total
10 benzophenones, including guttiferone A, as determined by the method described in Dal Molin MM, et al., (2012) “Phytochemical analysis and antinociceptive properties of *Garcinia achachariu* Rusby (Clusiaceae) seeds.” Arch Pharm Res 35: 623-631.

As used in the description and the appended claims, the singular forms “a,” “an,” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. All percentages disclosed herein are by weight of the total composition, unless specifically stated otherwise. All ratios are weight ratios, unless specifically stated otherwise.
15 The number of significant digits conveys neither a limitation on the indicated amounts nor on the accuracy of the measurements. All numerical amounts are understood to be modified by the word “about” unless otherwise specifically indicated. All measurements are understood to be made at 25°C and at ambient conditions, where “ambient conditions” means conditions under
20 about one atmosphere of pressure and at about 50% relative humidity. All such weights as they pertain to listed ingredients are based on the active level and do not include carriers or by-products that may be included in commercially available materials, unless otherwise specified. All numeric ranges are inclusive of narrower ranges and combinable; delineated upper and lower range limits are interchangeable to create further ranges not explicitly delineated.

The compositions of the present invention can comprise, consist essentially of, or consist
25 of, the essential components as well as optional ingredients described herein. As used herein, “consisting essentially of” means that the composition or component may include additional ingredients, but only if the additional ingredients do not materially alter the basic and novel characteristics of the claimed compositions or methods.

Definitions

30 “About,” as used herein, modifies a particular value, by referring to a range equal to the particular value, plus or minus twenty percent (+/- 20%) or less (e.g., less thanb 15%, 10%, or even less than 5%).

“Apply” or “application”, as used in reference to a composition, means to apply or spread the compositions of the present invention onto a human skin surface such as the epidermis.

“Derivative” means a molecule similar to that of another one, but differing from it with respect to a certain functional moiety (e.g., esters, ethers, amides, amines, carboxylic acids, hydroxyls, acetyls, thiols, halogens, thiols, and/or salt derivatives of the relevant molecule).

“Dermatologically acceptable” means that the compositions or components described are suitable for use in contact with human keratinous tissue without undue toxicity, incompatibility, instability, allergic response, and the like.

“Effective amount” means an amount of a compound or composition sufficient to significantly induce a positive benefit to skin, such as a health, appearance, and/or feel benefit, including, independently or in combination, the benefits disclosed herein, but low enough to avoid serious side effects (i.e., to provide a reasonable benefit to risk ratio, within the scope of sound judgment of the skilled artisan). An “effective amount of achachariu” is an amount of achachariu sufficient to regulate a desired skin condition of mammalian keratinous tissue when topically applied thereto in a skin care composition.

“Exogenous solvent” means any solvent placed in contact with the plant material for the purpose of separating compounds from the plant material. It may be a solvent originally present in plant material but added in higher amounts (e.g., in case of water extracts), or a solvent not inherently present in plant material. Plant material herein can include any solid or liquid portion of the AchachariuAchachariu plant.

“Extract,” when referring to achachariu, means a material (e.g., one or more phytochemicals) obtained from a portion of achachariu plant material (e.g., peel, fruit, seed, stem, bark, leaves, roots, and/or a combination of these), which may be fresh, dried, or partially dried, by contacting the plant portion(s) with an exogenous solvent and separating the desired material from the solvent using a conventional extraction process. Conventional extraction processes for obtaining plant extracts are well known in the art.

“Regulating a skin condition,” as used herein, means improving the health, appearance, and/or feel of skin.

“Salts” refer to ionic forms of a given compound combined with counterions deemed acceptable for a given application (e.g., food, topical, pharmaceutical). Examples include but are not limited to sodium, potassium, calcium, ammonium, manganese, copper, and/or magnesium salts of a given compound.

“Skin care” means regulating and/or improving a skin condition. Some non-limiting examples include improving skin appearance and/or feel by providing a smoother, more even appearance and/or feel; increasing the thickness of one or more layers of the skin; improving the elasticity or resiliency of the skin; improving the firmness of the skin; and reducing the oily, shiny, and/or dull appearance of skin, improving the hydration status or moisturization of the skin, improving the appearance of fine lines and/or wrinkles, improving skin exfoliation or desquamation, plumping the skin, improving skin barrier properties, improving skin tone, reducing the appearance of redness or skin blotches, and/or improving the brightness, radiancy, or translucency of skin.

“Skin care active” means an active that, when applied to skin, provides an acute and/or chronic benefit to skin or a type of cell commonly found therein. Skin care actives may regulate and/or improve skin or its associated cells (e.g., improve skin elasticity, hydration, skin barrier function, and/or cell metabolism).

“Skin care composition” means a composition that includes a skin care active and regulates and/or improves a skin condition.

“Topical” refers to a composition that is intended to be applied to a bodily surface such as skin or hair.

Skin Care Composition

The skin care compositions suitable for use in the methods herein include a safe and effective amount of achachariu (*Garcinia humilis*). The achachariu may be in form of a serum fraction, an extract, a powder, a juice, or a combination thereof. The achachariu may be obtained from any part of the *Garcinia humilis* plant, as desired, but it may be particularly desirable to use the achachariu fruit or a portion thereof (e.g., peel, pulp, and/or seed). Some testing suggests that the achachariu fruit, especially the peel, may contain higher concentrations of biologically active compounds (e.g., carbohydrates, citric acid, flavonoids, xanthonones and tannins) than other parts of the achachariu plant for regulating particular conditions of mammalian keratinous tissue. The achachariu extract and/or serum fraction may be obtained according to the methods described in more detail below and combined with a dermatologically acceptable carrier, along with any optional ingredients, using conventional methods of making skin care compositions. The personal care composition may then be packaged for commercial distribution.

FIG. 1 illustrates the distinct layers and parts of the achachariu fruit, as shown by a section passing through a long axis of the fruit. Whole fruit, a particular part of fruit, or any combination of parts of fruit may be used to provide a serum fraction or extract herein.

However, this is not meant to exclude further distinctions of fruit parts than described here, or leaves that may be retained during harvesting. As shown in FIG. 1, the outermost layer of the achachariu fruit is the “Peel”, which is comparatively thick and tough. The next inward layer is the “Flesh”, which is comparatively soft and yielding. The flesh surrounds a comparatively large “Seed”. Especially large fruit may have more than one seed.

The amount of achachariu that is “effective” can differ from one particular source (e.g., manufacturer) to another, and can be determined by the skilled artisan based upon a particular product’s level of activity (e.g., level of active components present). The concentration of active components in the particular achachariu product to be used will depend on factors such as the final dilution volume of the product, the particular method employed, the natural range of variation among individual plants, and other common factors known to those skilled in the art. In some instances, an effective amount of achachariu may range from 0.01% to 15% (e.g., from 0.1% to 10%, 0.2% to 7%, 0.5% to 5%, or even 1% to 3%).

The skin care compositions herein are intended for topical application to skin, and are formulated accordingly (e.g., have suitable viscosity, color, fragrance, and feel properties). The present skin care compositions may be provided in a variety of forms, including, but not limited to, emulsions, lotions, milks, liquids, solids, creams, gels, mousses, ointments, pastes, serums, sticks, sprays, tonics, aerosols, foams, and/or pencils.

FIG. 2 illustrates an exemplary method for providing bioactive achachriu ingredients. It is to be appreciated that portions of the process referring to “fruit” can include any portion of the achachariu plant, as desired. The individual steps illustrated in FIG. 2 are described in more detail below.

“Cleaning” involves the removal of debris from the harvested achachariu plant material, prior to further processing, in a way that avoids injury to the fruit or removal of juice or other desirable components. For example, cleaning can be performed by low-pressure rinsing with potable water, under conditions where residual water wash would not noticeably contain plant pigments.

“Selection of material” involves separating various parts of the achachariu plant material to further process a particular part alone, or in combination with other parts. This includes, but is not limited to: selecting whole fruit, peel, flesh, seed and/or leaves for further processing.

“Maceration” is an optional step for rendering the plant material and/or selected parts of the plant material into smaller particles and otherwise disrupting the integrity of the fruit to ease

the following expelling of liquid juice. If the selected plant material is especially yielding (such as the flesh of the fruit) or otherwise deemed suitable for conditions and equipment of the pressing step, maceration may be omitted. Examples of suitable maceration implements include, but are not limited to, devices such as a crusher, a grinder, or a mill (e.g., knife mill or hammer mill). To prevent temperature-induced degradation of plant material, maceration can include temperature monitoring and selection of maceration parameters which minimize the risk of temperature increase during this step.

“Pressing” involves the application of mechanical force to the selected, and optionally macerated, achachariu plant material to separate at least some of the liquid component from the rest of the plant material. The applied mechanical force may be provided by any suitable means known in the art (e.g., ambient gravity, centrifugal force from a rotary expeller, pressure from the piston of a hydraulic press, or rollers or a screw of appropriate type of press).

“Mechanical separation” involves the removal of relatively large achachariu particles (e.g., pulp or agglomerated/aggregated cloud particles) from the liquid component of the achachariu plant material.

“Juice” refers to the liquid material expelled from achachariu plant material as a result of pressing. Juice can contain solid particles, semi-solid particles, and/or droplets of water-immiscible liquids of a variety of sizes (collectively referred to as “achacaha particles”) in an aqueous serum. Achachariu particles, based on size and ease of removal, can be qualitatively described as either “pulp” or “cloud”. While details depend on properties of the involved materials (e.g. whole fruit versus selected parts) and exact processing parameters, an example of a size boundary between “pulp” and “cloud” could lie between about 1 and about 100 microns.

“Pulp” refers to relatively large achachariu particles present in juice and those same achachariu particles removed from the juice by mechanical separation. It is not uncommon to see and distinguish individual pulp particles with a naked eye. Pulp particles suspended in the juice are amenable to removal by mechanical separation, including, but not limited to, sedimentation by ambient gravity, skimming, passing through a mesh or a filter, or centrifugation.

“Cloud” refers to relatively small achachariu particles present in the achachariu juice, and may even include dissolved compounds (e.g., high molecular weight compounds such as proteins and polysaccharides), which can be readily induced (e.g., by coagulation or temperature change) to form particles. Cloud particles are typically visible as turbidity of the achachariu juice, and individual cloud particles are generally indistinguishable to the naked eye. Cloud particles are

generally dispersed in the achachariu juice and such dispersions tends to remain stable for a longer period time than a pulp suspension, especially colloidal components of the cloud. Removal of cloud particles by mechanical means such as those used for pulp removal can be difficult.

5 “Destabilizing treatment” generally involves exposing a material to electromagnetic waves in order to modify one or more physical properties of the material (e.g., the real component of low-frequency dielectric constant). With regard to achachariu juice, destabilization treatment degrades stability of the particle dispersion in the juice by causing agglomeration and/or aggregation of particles (especially cloud particles) into assemblies that are sufficiently
10 large and stable to enable and/or improve their subsequent removal by mechanical separation techniques such as those described above for pulp removal.

“Serum” refers to liquid portion of achachariu juice remaining after pulp and cloud, as well as possible contaminants of concern, has been removed. Achachariu serum is free or substantially free of achachariu particles.

15 “Finished ingredient” refers to serum, extract, and/or particle-free extract that is in a form suitable for subsequent sale and/or incorporation into a personal care product. The finished ingredient may include preservatives that protect the serum, extract, particle-free extract, and/or compositions containing the same against environmental challenges such as temperature, atmosphere (e.g., oxygen), light, and microorganisms. It is to be appreciated that an ingredient
20 free of preservatives is also contemplated herein. Surprisingly, it has been found that the processes described herein produce finished ingredients with multifunctional biological activities that are either free of or substantially free of benzophenones and proteins.

“Post-destabilization precipitate” refers to achachariu particles removed from the juice via mechanical separation following destabilizing treatment.

25 “Solvent extraction” in FIG. 2 involves conducting an extraction on achachariu particles removed from the achachariu juice with one or more solvents (e.g., dipropylene glycol).

The extract shown in FIG. 2 refers to the solution resulting from the solvent extraction of the achachariu pulp and post-destablization precipitate. In some instances, any achachariu particles remaining in the extract may be separated (e.g., mechanically) to yield a particle-free
30 extract. The extract and/or particle-free extract may serve as a finished ingredient, or as a base for a finished ingredient via addition of preservatives.

“Post-extraction precipitate” refers to achachariu particles separated from the extract in FIG. 2.

Achachariu Serum Fraction

The compositions herein may include an achachariu serum fraction and/or a salt, isomer, or derivative thereof. Serum fraction techniques involve separating the fresh cell juice found in plant material from the rest of the plant matter and processing the juice to provide a stable, refined serum. Examples of achachariu serum fractions that may be suitable for use in the compositions and methods herein include Recentia[®] GH (whole fruit) and Recentia[®] GH-P (peel only) from Ashland Specialty Ingredients. Achachariu peel serum fraction has the INCI designation “Garcinia Humilis Peel Extract” and the CAS No. 1622986-60-0.

The achachariu serum fractions herein may be prepared from fresh achachariu using a method that helps maintain the integrity of the bioactive components present in the achachariu plant material. Care should be taken to preserve the achachariu plant material integrity during harvesting and transport, so as to minimize environmental factors such as moisture loss and biological degradation. All steps of the serum fraction making process should be completed in the shortest possible period of time to minimize exposure of the fresh achachariu plant material to sun, high temperature, and other undesirable environmental factors. Harvesting (e.g., by hand or mechanical cutting) should be conducted in a manner that avoids or minimizes the chopping, mashing, crushing, or other type of injury to the achachariu plant material to be used (e.g., fruit). Harvest and transport of achachariu plant material should be conducted in a manner to avoid moisture loss or spoilage. After harvesting, the achachariu plant material (e.g., fruit, leaves) is cleaned to remove debris prior to further processing. Cleaning is performed under conditions to prevent the initiation of the release of the juice from the fruit, to cause injury, or to remove valuable components. For example, the harvested achachariu plant material may be washed with water at low-pressure (e.g., 1 kg/cm² or less) for a short duration (e.g., 5 minutes or less). Excess water is removed from washed fruit biomass before processing.

The washed plant material is processed (e.g., macerated and pressed) to yield juice. In some instances, the whole fruit or a portion thereof (e.g., peel, fruit flesh, and/or seed) is macerated (e.g., by grinding) and then pressed to separate the juice from the rest of the plant matter. For example, a hammer mill may be used to grind the whole fruit to yield plant material particles of a desired size (e.g., less than or equal to 0.5 cm) in a short time (e.g., 10 seconds or less) and without significant increase of biomass temperature (e.g., 5° C or less). The separation of juice from the achachariu plant material is commenced promptly, as soon as possible, after

maceration of the achachariu plant to avoid a significant increase in temperature of the juice and/or pulp. For example, macerated achachariu leaves can be pressed using a horizontal, continuous screw press, wherein the pressure on the cone is maintained at 24 kg/cm², screw speed is at 12 rpm, and biomass temperature increase is 5°C or less.

5 The achachariu juice can be subjected to further processing immediately, or the juice may be frozen at about -30° C and thawed and processed later.

Achachariu juice typically contains a variety of achachariu particles (i.e., pulp and cloud) in an aqueous serum. Thus, in order to obtain the desired serum fraction, all or substantially all of the achachariu particles should be removed from the juice. In some instances, it may be desirable to provide a serum fraction that includes less than 25% dry matter (e.g., less than 20%, 10 15%, 12%, 10% or even less than 9% dry matter). The pulp may be removed from the achachariu juice using a suitable mechanical separation technique such as, for example, straining, filtration (including filtration utilizing a pressure gradient), skimming, sedimentation by ambient gravity, decanting, centrifugation, and/or a combination of these to yield pulp-free or 15 substantially pulp-free juice. The cloud may be removed by exposing the juice to electromagnetic waves to destabilize the cloud dispersion in the juice. The frequency of electromagnetic waves may range between 300 MHz and 50 GHz. Suitable devices for generating such electromagnetic waves include, but are not limited to magnetrons, power grid tubes, klystrons, klystrodes, crossed-field amplifiers, travelling wave tubes, and gyrotrons. In 20 some instances, a magnetron operating at a frequency of 915 MHz, 2.45 GHz, and 5.8 GHz can allow the value of real component of low-frequency dielectric constant (ϵ''_0) to be decreased during the treatment by between 10 and 40 compared to its value prior to treatment. The value of real component of low-frequency dielectric constant (ϵ''_0) can be determined using broadband dielectric spectroscopy data obtained via equipment and software from Agilent Technologies: 25 PNA-L Network Analyzer N5230C with 85070E dielectric probe kit, N4693-60001 electronic calibration module, and 85070 software. The calculation is performed according to method described in the article Cole, K. S., & Cole, R. H. (1941). Dispersion and absorption in dielectrics I. Alternating current characteristics. The Journal of Chemical Physics, 9(4), 341-351.

Other non-limiting examples of techniques for providing serum fractions are disclosed in 30 U.S. Patent Nos. 7,442,391 and 7,537,791 to Koganov and U.S. Pub. No. 2012/0201768, filed by Swanson, et al.

The compositions and methods herein may employ an achachariu extract. An achachariu extract is obtained by separating compounds from achachariu plant matter with an exogenous solvent. Consistent with the general principle of “like dissolves like,” the choice of extraction solvent largely determines the type and number of compounds that will result from any particular extraction technique. For instance, polar compounds are typically extracted out by using a polar solvent, while non-polar compounds are extracted out by using a non-polar solvent. The correlation between solvent polarity and the types of materials isolated using traditional solvent extraction is described in Houghton & Raman, *Laboratory Handbook for the Fractionation of Natural Extracts* (1998).

The achachariu extracts herein may be obtained using any suitable extraction technique known in the art. In some instances, the achachariu extract may be obtained by the following procedure: (i) place the desired portion of dried plant material (e.g., whole fruit, fruit pulp, peel, seeds, stem, bark, leaves) in a conical glass percolator; (ii) add the indicated percentage of extraction solvent in a w/w ratio of 1 part plant material to 2 parts extraction solvent (when the indicated percentage of extraction solvent is less than 100%, the remaining solvent is water (e.g., 95% ethanol with 5% water, 50% ethanol with 50% water)); (iii) allow the extraction to proceed for 16 to 24 hours; (iv) collect the percolate, and repeat the above process until the resulting percolate is substantially free from plant additional extract; (v) combine the percolates, evaporate to dryness under reduced pressure, and store the resulting extract under nitrogen at less than 4 degrees Celsius. Extracts may be used without any further modification or may be modified (e.g., ethoxylated, esterified) to form a derivative material.

Achachariu Powder or Juice

The personal care compositions for use with the methods herein may include an achachariu powder or juice. Achachariu juice may be obtained by macerating and process achachariu plant material, for example, as described hereinabove. Achachariu powder may be obtained by drying achachariu plant material and processing the dried material into particles. Additionally or alternatively, the achachariu plant material may be processed into particles and then dried. Processing the achachariu into particles may include one or more grinding steps performed before and/or after drying. The achachariu biomass may be dried and processed into particles using any suitable method known in the art. The achachariu powder may have a weight average particle size of from 50 to 750 microns. Once the achachariu is processed into particles of the desired size, the powder can be incorporated into a personal care composition using conventional methods for making such compositions.

Dermatologically Acceptable Carrier

The skin care compositions herein include a dermatologically acceptable carrier at an amount of 20% to 99.99% (e.g., 50% to 99%, 60% to 98%, 70% to 95%, or even 60% to 80%) by weight of the composition. The carrier may be aqueous or anhydrous. The form of the carrier is not particularly limited, and can be any suitable form known in the art for the application desired (e.g., solutions, dispersions, emulsions and combinations thereof). “Emulsions” refer to compositions having an aqueous phase and an oil phase. Emulsion carriers include, but are not limited to oil-in-water, water-in-oil and water-in-oil-in-water emulsions. Emulsion carriers herein may include from 0.01% to 10% (e.g., 0.1% to 5%) of an emulsifier (e.g., nonionic, anionic, cationic emulsifier, or a combination thereof). Suitable emulsifiers are disclosed in, for example, U.S. Patent 3,755,560, U.S. Patent 4,421,769, and McCutcheon's Detergents and Emulsifiers, North American Edition, pages 317-324 (1986).

Optional Ingredients

The compositions of the present invention may contain a variety of optional ingredients that are conventionally used in skin care compositions, as long as the optional ingredient(s) do not undesirably alter product stability, aesthetics or performance. The optional ingredients, when incorporated into the composition, should be suitable for contact with human skin without undue toxicity, incompatibility, instability, allergic response, and the like within the scope of sound judgment. The CTFA Cosmetic Ingredient Handbook, Second Edition (1992) describes a wide variety of nonlimiting cosmetic and pharmaceutical ingredients. The compositions herein may include 0.0001 % to 50%; from 0.001 % to 20%; or even 0.01% to 10%, by weight of the composition, of optional ingredients. Some non-limiting examples of optional ingredients include vitamins, minerals, peptides and peptide derivatives, sugar amines, oil control agents, flavonoid compounds, anti-oxidants and/or anti-oxidant precursors, preservatives, phytosterols, protease inhibitors, tyrosinase inhibitors, anti-inflammatory agents, moisturizing agents, emollients, humectants, exfoliating agents, skin lightening agents, sunscreens, sunless tanning agents, pigments, film formers, thickeners, pH adjusters, opacifying agents, colorings/colorants, particles, fragrances, essential oils, lubricants, anti-acne actives, anti-cellulite actives, chelating agents, anti-wrinkle actives, anti-atrophy actives, phytosterols and/or plant hormones, N-acyl amino acid compounds, antimicrobials, antifungals, and combinations of these. Other non-limiting examples of skin care actives can be found in U.S. Pub. Nos. 2010/0272667 and 2008/0206373 and U.S. Pat. No. 8,790,720.

Methods of Regulating a Skin Condition

Skin care compositions comprising an effective amount of achachariu can be used to regulate a skin condition by topically applying the skin care composition to a portion of mammalian tissue in need of treatment or where treatment is desired. Identifying a target portion of skin may be based on, for example, the presence of a visible condition (e.g., dryness, undesirable feel, redness, inflammation, discoloration, or wrinkles). In some instances, the target portion of skin may not exhibit visible signs of a skin condition, but a user may still wish to target such an area if it is one that is known to develop a condition (e.g., skin surfaces that are typically not covered by clothing).

Skin care compositions containing an effective amount of achachariu may be applied once a day, twice a day, or on a more frequent daily basis, during a treatment period. The treatment period is ideally of sufficient time for the achachariu to provide the desired benefit. For example, the treatment period may be of sufficient time for the achachariu to provide a noticeable and/or measurable improvement in a hair or skin condition. The treatment period may last for at least 1 week (e.g., about 2 weeks, 4 weeks, 8 weeks, or even 12 weeks). In some instances, the treatment period will extend over multiple months (*i.e.*, 3-12 months) or multiple years. In some instances, a cosmetic composition containing an effective amount of achachariu may be applied most days of the week (e.g., at least 4, 5 or 6 days a week), at least once a day or even twice a day during a treatment period of at least 2 weeks, 4 weeks, 8 weeks, or 12 weeks.

The skin care compositions herein may be applied locally or generally. In reference to application of the composition, the terms “localized”, “local”, or “locally” mean that the composition is delivered to the targeted area while minimizing delivery to skin surfaces where treatment is not needed or desired. While certain embodiments herein contemplate applying a composition locally to an area, it will be appreciated that the compositions herein can be applied more generally or broadly to one or more skin surfaces. In certain embodiments, the compositions herein may be used as part of a multi-step beauty regimen, wherein the present composition may be applied before and/or after one or more other compositions.

Using the skin care compositions herein according to the present methods can provide a skin benefit. Some non-limiting examples of skin benefits include reducing the appearance of wrinkles, deep lines, fine lines, crevices, bumps, large pores; increasing the convolution of the dermal-epidermal border; skin lightening; increasing elasticity, decreasing sagging, reducing cellulite; reducing the appearance of under-eye circles, reducing the appearance of discoloration, reducing hyperpigmentation, increasing skin luminosity, and combinations thereof.

The skin care compositions may be applied by any suitable means known for applying such products, including rubbing, wiping or dabbing with hands, fingers and/or an implement. Non-limiting examples of implements include a sponge or sponge-tipped applicator, a swab (for example, a cotton-tipped swab), a pen optionally comprising a foam or sponge applicator, a brush, a wipe, and combinations thereof. The composition may be pre-applied to the applicator and, for example, delivered to the user pre-packaged as such, or the user may be instructed to apply the composition to the applicator prior to use. In some instances, the composition may be stored in an implement, for example, in a separate storage area for the composition. In this example, the composition may be transferred to the applicator from the storage area, for example, by squeezing and/or breaking or by other suitable means. The composition may be applied to the keratinous tissue by contacting the applicator and composition to the skin. Contact may include, for example, light pressure, dabbing, rubbing, wiping, or any other suitable means. When targeted application is desired, the composition may be applied to the desired area of keratinous tissue.

15 Methods for Determining the Effectiveness of Achachariu

Irritation and inflammation in human skin can lead to visible signs of skin aging (e.g. discoloration and wrinkles), decreased mechanical strength, decreased protective functions, and lessened ability to recover from stress and injuries. Ubiquitous stressors such as sunlight and surfactants can be especially problematic. Mitigating irritation and inflammation of the skin, particularly those caused by common stressors, is important and desirable.

The adverse effects of light, most commonly sunlight (though artificial sources are included), on human skin are well known. Overly high exposure to sunlight may cause acute adverse reaction involving irritation and inflammation, such as sunburn. Exposures insufficient to cause acute reactions can still trigger inflammation-related processes. Accumulated inflammatory damage from sunlight exposure causes degradation of skin resilience and development of an undesirable appearance (i.e., photoaging).

Surfactants are also known to cause adverse reactions on human skin. Surfactants are used in a variety of personal care and cleansing products to allow or improve processes of cleansing, foaming, emulsifying, solubilizing, and dispersing. Repetitive contact with surfactant-containing products has been shown to cause damage of the skin barrier due to surface or interface activities of the surfactants, which can be perceived by consumers as dryness, itchiness, swelling, redness, and/or pain. The weakened barrier subsequently leads to deeper penetration of the surfactants into skin and induced irritation and inflammation. As surfactants are widely used

in hand soaps, facial and body washes, shampoos and conditioners, as well as dish, laundry and housecleaning detergents, human skin contact with surfactants is common.

Irritation and inflammation are commonly viewed as a “cascade” proceeding from necessary release of a signaling compound Interleukin (IL) 1-alpha (or IL-1 α) to induction of other downstream cytokines and chemokines such as interleukins IL-6 and IL-8 or other signaling molecules (Welss T, Basketter DA, Schröder KR. In vitro skin irritation: facts and future. State of the art review of mechanisms and models. Toxicol In Vitro 2004; 18 (3): 231-43). However, previously published data suggest that “cascade” view might not be a comprehensive model.

It has been shown that sodium dodecyl sulfate (SDS), a single compound commonly used as a benchmark source of surfactant stress in both *in vitro* and *in vivo* studies, can trigger different portions of the irritation and inflammation process without significantly affecting release of a primary cytokine such as IL-1 α , depending on concentration. The complexity of irritation and inflammation response of skin cells implies that signaling “network” model is a more adequate analogy than a signaling “cascade” model. This indicates that mitigation of such a complex signaling process must affect more than one pathway, such as by using a multifunctional bioactive ingredient.

One of the methodologies for studying and quantifying irritation and inflammation includes culturing cells of the tissue most likely to come in contact with stress sources, such as viable epidermal keratinocytes from human skin. Human epidermal keratinocytes (HEK) have become the focus of attention in irritant-induced skin inflammation by virtue of their epidermal location, importance in maintaining the integrity of the stratum corneum barrier, and the ability to produce a variety of inflammatory mediators. Keratinocytes can release a variety of signalling substances (e.g., interleukins and arachidonic acid metabolites) in response to a range of irritants, including surfactants and sunlight. The amounts of these signalling substances present in a tissue sample can be measured via techniques such as Enzyme-Linked Immunosorbent Assay (ELISA). Bioactive substances that reduce the release of inflammatory signalling substances may help control the signs of irritation and inflammation in human skin.

Besides signalling substances, other very important compounds in processes of irritation and inflammation are those that directly cause the damage. Especially notable inflammatory damage substances are free radicals (especially reactive oxygen species) and protein-degrading enzymes (proteases). It is possible to detect the presence or measure the activity of such damaging substances by incubating them with a substrate they can alter or degrade. The

alteration or degradation of the substrate can be measured directly (e.g., by loss or development of color or fluorescence) or indirectly (e.g., by ELISA). In some cases, the presence or activity of damaging substances can be measured directly or indirectly, for example, with spectroscopic techniques (e.g., Electron Paramagnetic Resonance techniques and the use of chromogenic artificial stable free radicals like DPPH).

The tests selected for determining the effects of serum fractions and extracts of achachariu, and skin care compositions containing the same, include inhibition of proteases (damaging compounds) in non-cell-based bioassays, inhibition of chemokines, cytokines and prostaglandins (signalling compounds) in cultured human skin cells, inhibition of a compound capable of both signalling and causing damage in cultured human cells, and measuring release or lack thereof of substances indicating cell damage or sensitization. These tests illustrate safety (e.g., via a lack of cytotoxicity and sensitization potential) and the efficacy and potency of achachariu in inhibiting signalling and damaging compounds involved in skin irritation, inflammation, and aging processes. The cells in the assays described herein are normal human adult epidermal keratinocytes (HEK), unless specifically stated otherwise.

EXAMPLES

The following examples are provided for the purpose of illustration only and should in no way be construed as being limiting, but rather should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.

Example 1 - Preparation of a Serum Fraction from Achachariu Whole Fruit

In this example, achachariu (*Garcinia humilis*) whole fruit are used to produce a serum fraction. The achachariu fruit are harvested fresh from trees, inspected, and cleaned prior to processing. Unsound fruit is not used. Selected whole fruit are ground, pressed, and mechanically separated to provide juice and pulp. The yield of juice from achachariu whole fruit after grinding, pressing and mechanical separation is about 60 to 69% weight/weight; the pH of juice from achachariu whole fruit is from 3.0 to 3.3. The juice is immediately subjected to destabilizing treatment by electromagnetic waves in a continuous flow system that includes magnetrons operating at a frequency of 5.8 GHz. The parameters of the electromagnetic waves in the destabilization step are set to achieve the decrease in value of real component of low-frequency dielectric constant (ϵ'_3) during the treatment by about 20 Farads per meter (F/m) compared to its value prior to treatment. The de-stabilized juice is immediately pumped through

a continuous flow centrifuge to yield a serum and post-destabilization precipitate. The serum is substantially free of benzophenones and protein.

Example 2 - Preparation of Serum Fraction from Achachariu Peel

In this example, achachariu fruit peel is used to produce a serum fraction. The
5 achachariu fruit are harvested fresh from trees, inspected, and cleaned prior to processing. Unsound fruit is not used. The fruit peel is separated from whole fruits and then ground, pressed, and mechanically separated to produce juice and pulp. The yield of juice from achachariu fruit peel after grinding (maceration), pressing and mechanical separation is about 25
10 to 35% weight/weight; the pH of juice from achachariu fruit peel is 2.7 to 3.0. The juice from fruit peel is immediately subjected to destabilizing treatment by electromagnetic waves in a continuous flow system that includes magnetrons operating at a frequency of 2.45 GHz. The parameters of the electromagnetic waves in the destabilization step are set to achieve the decrease in value of real component of low-frequency dielectric constant ($\epsilon_{\text{G}}^{\prime}$) during the
15 treatment by about 30 Farads per meter (F/m) compared to its value prior to treatment. The destabilized juice is immediately pumped through a continuous flow centrifuge to yield a serum and post-destabilization precipitate. The serum is free or substantially free of benzophenones and protein.

Example 3 - Preparation of Serum Fraction from Achachariu Fruit Flesh and Seeds

In this example, achachariu fruit flesh and seeds are used to produce a serum fraction.
20 The achachariu fruit are harvested fresh from trees, inspected, and cleaned prior to processing. Unsound fruit is not used. The fruit flesh and seed are separated from whole fruits and then ground, pressed and mechanically separated to produce juice and pulp. The yield of juice from Achachariu (*Garcinia humilis*) fruit flesh and seeds after grinding, pressing and mechanical
25 separation is about 30 to 40% weight/weight; the pH of juice from achacha fruit flesh and seeds is 3.8 to 4.2. The juice is immediately subjected to destabilizing treatment by electromagnetic waves in a continuous flow system that includes magnetrons operating at a frequency of 2.45 GHz. The parameters of the electromagnetic waves in the destabilization step are set to achieve the decrease in value of real component of low-frequency dielectric constant ($\epsilon_{\text{G}}^{\prime}$) during the
30 processing by about 25 Farads per meter (F/m) compared to its value prior to treatment. The destabilized juice is immediately pumped through a continuous flow centrifuge to yield a serum and post-destabilization precipitate. The serum is free or substantially free from benzophenones and protein.

polymethylsilsesquioxane	1.25	2.50	2.00	0.50	1.25	1.25	1.25
Phase C							
Polyethylene	1.50	1.00	1.50	2.00	1.50	1.50	1.50
Phase D							
Water	5.00	10.00	10.00	5.00	5.00	5.00	5.00
Achachariu serum fraction	0.1	0.5	2.0	10.0	-	-	-
Achachariu extract	-	-	-	-	0.1	0.5	2
dexpanthenol	0.25	0.50	0.50	2.00	0.25	0.25	0.25
Phase E							
benzyl alcohol	0.25	0.25	0.25	0.25	0.25	0.25	0.25
dimethicone/dimethiconol	0.5	1.00	2.00	0.25	0.5	0.5	0.5

Example 6 - Preservatives

Various preservatives were tested for use with the bioactive serum fractions and bioactive extracts of achacha herein. Table 2 shows an example of combination/concentrations of preservatives that may be particularly for preparing finished achacha ingredients (e.g., prepared from the serum fractions described in Examples 1, 2, and 3). It has been found that the preservatives listed in Table 2 help prevent the formation of precipitates in a finished product.

Table 2

Preservative	Amount (wt %)
Pentylene Glycol (CAS 5343-92-0)	1.90%
Tetrasodium EDTA (CAS 64-02-8)	0.25%
Sodium metabisulfite (CAS 7681-57-4)	0.20%
Potassium sorbate (CAS 590-00-1)	0.10%
Sodium Benzoate (CAS 532-32-1)	0.10%
Bioactive Serum Fraction or Extract	97.45%

10

Example 7 - Physico-Chemical Characteristics

Table 3 illustrates methods for testing and evaluating certain physico-chemical characteristics of achacaha serum fractions and extracts. It is to be appreciated that the methods are not limited to the specific instruments or techniques shown, and equivalent instruments and techniques may be used to achieve substantially the same results, as known by those skilled in the art.

15

Table 3

Property	Test Method	Units
----------	-------------	-------

Property	Test Method	Units
Appearance	Determined organoleptically.	N/A
Odor	Determined organoleptically.	N/A
Color	Determined on Lovibond Comparator 3000 Gardner Scale. Turn on comparator lamp. Measure 8mL of sample into sample tube. Insert tube into comparator. Rotate the knobs until two color standards nearest in color to the sample have been located. Record the value of the sample color accordingly. If the color of the sample is substantially similar to both, rather than a single standard, then record it as a value between the values of the two standards.	Gardner scale
Dry Matter	Dry matter is determined by comparing the weights of liquid sample with residual dry matter after water has been evaporated. Procedure is based on standard laboratory practices commensurate with available equipment. Select a suitable aluminum weighing dish (e.g., VWR 25433-016) and weight the dish. Add approximately 4mL of liquid sample to the dish with the dish on the scale. Determine the weight of the liquid sample by subtracting the dish weight from the total weight. Repeat this procedure with two additional weighing dishes. Place the dishes in a ThermoScientific "Lindberg Blue M" Gravity oven at 105 degrees Celsius for 24 hours. After 24 hours, remove the dishes and allow them to cool for approximately 5 minutes at room temperature. Weigh each dish. Determine the weight of the dry sample. Calculate dry matter percentage by dividing dry sample weight by liquid sample weight. Dry matter percentage for the sample is the average of the dry matter percentages for the three dishes.	%
Refractive index	Determined using a Reichert Arias™ 500 brand refractometer according to instruction manual sections 6.0, 4.1 and 4.4-4.5. Temperature regulation is provided by Cole-Parmer Polystat temperature controller, model number 12108-10 set at 20 C. Automatic Reading Method is enabled. Place 0.5mL of deionized water on the surface of the lower measuring prism, taking care to avoid bubble formation. Close the cell and turn the shadowline adjustment knob to bring the shadowline within the crosshairs. Wait for temperature at refractometer measuring cell to stabilize, then push Read button. Repeat until refractive index of deionized water is determined as 1.333 at least three times in a row. Rinse the lower and upper surfaces of the measuring cell with deionized water and blot dry with lint-free wipe. Place 0.5mL of sample on the surface of the lower measuring prism. Close the cell and turn the shadowline adjustment knob to bring the shadowline within the crosshairs. Wait for temperature at refractometer measuring cell to stabilize, then push Read button. Repeat until stable readings have been obtained for sample material at least three times in a row. Record this value as the Refractive Index.	nD

Property	Test Method	Units
Density	Determined with Densito 30PX densitometer from Mettler Toledo. Procedure is based on Operating Instructions for Densito 30PX, sections 4 and 6. Set the instrument display to g/cm ³ . Calibrate the instrument with 4 cm ³ of deionized water, avoiding bubble intake or formation. If the density of the calibration sample deviates by more than 0.05% from the expected density of water at ambient temperature, recalibrate the densitometer as per Operating Instructions. Eject the calibration sample and fill the sample loops with 4 cm ³ of sample, avoiding bubble intake or formation. Record the reading. Eject the sample and repeat steps above for additional readings, until receiving three matching readings in a row. Record the value of density (specific gravity) for the sample.	g/cm ³
pH	Determined by measuring on a Denver Instrument Model 250 pH / ISE / conductivity meter with pH / ATC electrode number 300729.1. Procedure is based on manufacturer's 301127.1 Rev. D manual, pages ii and 9 through 12. Use pH 4.01 and pH 7.00 buffers to calibrate the pH meter.	N/A
Total Plate Count	Determined as per US Pharmacopoeia XXX, NF25, <61>, Microbiological Limit Tests	CFU / gm
Mold / Yeast	Determined as per US Pharmacopoeia XXX, NF25, <61>, Microbiological Limit Tests	CFU / gm
<i>E. coli</i>	Determined as per US Pharmacopoeia XXX, NF25, <61>, Microbiological Limit Tests	CFU / gm
<i>Salmonella</i> sp.	Determined as per US Pharmacopoeia XXX, NF25, <61>, Microbiological Limit Tests	CFU / gm
<i>Staphylococcus aureus</i>	Determined as per US Pharmacopoeia XXX, NF25, <61>, Microbiological Limit Tests	CFU / gm
<i>Pseudomonas</i> sp.	Determined as per US Pharmacopoeia XXX, NF25, <61>, Microbiological Limit Tests	CFU / gm
Benzophenones,	Dal Molin MM, Silva S, Alves DR, Quintão NLM, Delle Monache F et al.(2012) Phytochemical analysis and antinociceptive properties of <i>Garcinia achachariu</i> Rusby (Clusiaceae) seeds. Arch Pharm Res 35: 623-631.	%
Protein	Amino acid analysis conducted on Hitachi L-8900 amino acid analyzer according the manufacturer's instructions.	%

Some physico-chemical characteristics of the present achacha serum fractions and extracts are illustrated in Tables 4, 5, and 6 below. The serum fractions and extracts are prepared according to the methods described in the corresponding example(s) above. The achacha serum fraction included in the finished ingredient Recentia® GH-P (CAS RN# 1622986-60-0), which is

5 illustrated in Table 6 below, is prepared according to the process described in Example 2.

Table 4 - Serum Fractions

Serums obtained from:	Whole Fruit Lot GH 0785	Fruit Peel Lot GH 1082	Fruit Flesh and Seed Lot GH 1083
Appearance	Clear Orange Liquid	Clear Orange Liquid	Hazy Yellow Liquid
Odor	Characteristic	Characteristic	Characteristic
Color (Gardner Scale)	6.5	8.5	6.5
Dry matter (%)	13.05	11.02	16.3
Refractive index (nD)	1.355	1.352	1.359
pH	3.06	2.85	4.03
Density, g/cm ³	1.0612	1.0514	1.0714
Protein	<0.07%	<0.13%	<0.15%
Benzophenones	<0.1%	<0.1%	<0.1%

Table 5 - Extracts

Extracts (1 part plant material +3 part solvent ratio, weight/weight) obtained from:	Whole Fruit Extracted at 4°C Lot. GH 0841	Fruit Peel Extracted at 4°C Lot GH (PE) 0837	Whole Fruit Extracted at 40°C Lot. GH 0842	Fruit Peel Extracted at 40°C Lot GH (PE) 0838
Appearance	Orange Liquid	Orange Liquid	Orange Liquid	Orange Liquid
Odor	Characteristic	Characteristi c	Characteristic	Characteristic
Color (Gardner Scale)	11.0	12.5	11.5	13.5
Refractive index (nD)	1.4315	1.4291	1.4314	1.4291
Protein	<0.046%	<0.049%	<0.041%	<0.046%
Benzophenones	About 0.1%	<0.1%	About 0.1% or higher	<0. 1%

Table 6 - Recentia® GH-P

Test Parameter	Result
Appearance	Clear Orange Liquid
Odor	Characteristic
Solubility in water	Soluble in any ratio
Color (Gardner scale)	5-12
Dry matter (%)	9.0-12.1
pH	2.9-3.8
Refractive index (nD)	1.349-1.355
Total Plate Count (CFU / g)	< 100

Test Parameter	Result
Mold / Yeast (CFU / g)	< 100
E. coli (CFU / g)	Negative / 10 g
Salmonella sp. (CFU / g)	Negative / 10 g
Staphylococcus aureus (CFU / g)	Negative / 10 g
Pseudomonas sp. (CFU / g)	Negative / 10 g

Example 8 - Absorbance Spectra

Absorbance spectra (in wavelength ranges 200-400 nm and 400-1000 nm) were obtained from 100 microliter samples of serum fractions and extracts of achachariu using a Synergy 2
5 multi-mode microplate reader (BioTek Instruments, Inc) with 96-well black quartz microplate (Hellma Analytics GmbH). All dilutions were done as volume/volume. Spectra of 100 microliter aliquots of respective solvents (ultrapure deionized water and fragrance grade dipropylene glycol) were subtracted from sample spectra. A summary of the absorbance spectra results are illustrated in FIGS. 3A, 3B, 4A, and 4B. FIGS. 3A and 4A illustrate absorbance spectra of a
10 wavelength range of 200-400 nm. The samples of achacha serum fractions and extracts analyzed in FIGS 3A and 3B included GH 0785, GH 1082, and GH 1083. The samples of achacha serum fractions and extracts analyzed in FIGS 4A and 4B included GH 0837, GH 0838, GH 0841, and GH 0842.

Example 9 – Biological Activity

15 Serums and finished ingredients prepared according to various embodiments herein were evaluated for biological activity of interest. The evaluations included in this example are: cytotoxicity; skin sensitization potential; inhibition of trypsin activity; inhibition of elastase activity; inhibition of Kallikrein 5; inhibition of IL-6, IL-8, and/or PGE2; ARE activation; melanin synthesis inhibition; and lipogenesis inhibition. The test methods and results of these
20 evaluations are discussed in more detail below.

Evaluation of Cytotoxicity

Lactate Dehydrogenase (LDH) is a key cytoplasmic enzyme. Presence of LDH outside the cells at levels above normal background leakage is an indicator of cell damage or cell death.
25 Assays quantifying LDH in cell culture medium are commonly employed to assess potential cytotoxicity. Observation of cells under a microscope that identify cell rupture or changes in cell morphology can also contribute to the assessment of cytotoxicity.

Normal human adult epidermal keratinocytes (HEK) and all cell culture supplies in the cytotoxicity evaluation were obtained from Life Technologies Co. (Carlsbad, CA, USA). The cells were grown and then maintained in keratinocyte basal medium 154 (M154) with added human keratinocyte growth supplements (HKGS) at 37°C in an atmosphere of 5% CO₂ and used
5 between passages 2 to 4. For the experiments, HEK cells were trypsinized, seeded in 96-well plates, and grown to ~80% confluence. HEK were then exposed, or not, to a stress factor, and incubated for 16 hours with or without test articles at various concentrations. After incubation, HEK cell supernatant medium samples were collected, and levels of LDH were evaluated using Cytoscan™ LDH Assay kit (Catalog # 786-210, produced by G-Biosciences, St. Louis, MO,
10 USA). Untreated, unstressed HEK cells were lysed using kit-supplied lysis buffer as a positive control, with lysate used as assay positive control and a measure of maximum LDH release. Lower induced LDH release, when confirmed by microscopy, indicates lower cytotoxicity.

Evaluation of Skin Sensitization Potential

It is possible for a material to not be cytotoxic, and yet be unsafe due to provoking an
15 allergic reaction upon skin contact. Typically, initial exposure to an allergen sensitizes the immune system, and following exposures cause an allergic response. Recent progress in understanding the mechanisms of skin sensitization identified interleukin-18 (IL-18) production in normal human epidermal keratinocytes (HEK) as a useful biomarker for skin contact sensitization (Corsini, et al., “Use of IL-18 Production In a Human Keratinocyte Cell Line to
20 Discriminate Contact Sensitizers from Irritants and Low Molecular Weight Respiratory Allergens.” *Toxicol In Vitro*. 2009 Aug; 23(5):789-96; Teunis, et al., “Transfer of a Two-tiered Keratinocyte Assay: IL-18 Production by NCTC2544 to Determine the Skin Sensitizing Capacity and Epidermal Equivalent Assay to Determine Sensitizer Potency.” *Toxicol In Vitro*. 2013 April; 27(3):1135-50). IL-18 is considered a suitable *in vitro* alternative to animal
25 skin sensitization testing methods such as the Local Lymph Node Assay. Thus, IL-18 production in HEK was evaluated to determine sensitization potential.

Normal human adult epidermal keratinocytes (HEK) were cultured as described above for the cytotoxicity evaluation. After incubation with test articles or controls for 16 hours, the HEK cells were lysed with 100 µl/well of 0.5% Triton X-100 in pH 7.4 Phosphate Buffered Saline
30 (PBS). The cell lysates were collected, and IL-18 was quantified using Human IL-18 ELISA Kit (Catalog # 7620, produced by MBL International Co., Woburn, MA, USA). A known skin sensitizer, *para*-phenylenediamine (*p*PD) (positive control), significantly induced IL-18 compared to vehicle control in HEK cultures. Fold changes of IL-18 levels between test articles

and respective vehicle controls were calculated and compared to *p*PD. Lower induction of IL-18 indicates lower sensitization potential.

Inhibition of Trypsin Activity

Collagen fibers provide mechanical strength and support for the skin. A ubiquitous protease, trypsin, is associated with damage and inflammation. Trypsin breaks down collagen, potentially leading to decreased mechanical strength of the skin, as well as wrinkles and darkening after stress or injury (Burns T, Breathnach S, Cox N, Griffiths C. Rook's Textbook of Dermatology. Eighth Edition. Wiley-Blackwell, 2010. Vol. 1 Sections 8.21 to 8.27. Vol. 2 Section 29.7).

Trypsin inhibition was determined via an EnzChek kit utilizing casein substrate with intra-molecularly quenched fluorescent label moieties (Catalog # E6638, produced by Life Technologies). Testing was conducted according to manufacturer instructions. Digestion buffer concentrate was diluted in deionized water. Substrate and bovine trypsin (Sigma catalog number T9201) were dissolved and diluted in the digestion buffer. Test articles were dissolved and diluted in digestion buffer. Calibration curve was constructed with amounts of trypsin ranging from 1000 nanograms to about 1.4 nanograms in reaction volume. Soybean trypsin inhibitor, type I-S (Sigma) was used as a positive control.

Amount of trypsin in wells with test articles and controls was fixed at 1000 nanograms. IC_{50} was calculated as concentration of test article in the reaction volume (e.g. microtiter plate well) necessary to reduce the trypsin activity to 50%. Lower IC_{50} values indicate higher potency and a degree of efficacy.

Inhibition of Elastase Activity

Elastin is a protein essential to elastic fiber network contained in connective tissues which depend on elasticity for their function, such as skin. Excessive elastase activity, commonly related to inflammation, degrades elastin and decreases strength and resilience of the skin. During inflammatory processes, elastase can be found in areas beyond those where it is produced or secreted. Human neutrophil elastase inhibition by test articles was determined in kinetic colorimetric assay described by Elastin Products Company, Inc. (Elastin Products Company. Assay with N-MeO-Suc-Ala-Ala-Pro-Val-pNA (EPC No. FH237) as substrate. Elastin Products Company, Inc. Research Biochemicals Catalogue. 2004. p.84) and modified for its use with 96-well microtiter plates (Corning 3641) from Corning, Inc. (and Synergy 2 microplate reader from BioTek Instruments, Inc.. The N-Methoxysuccinyl-Ala-Ala-Pro-Val-

pNA substrate (EPC, Catalog No: FH237), and elastase (EPC SE563) were from Elastin Products Company (Owensville, MI, USA). Working solution of elastase was prepared with 0.15 M pH 7.5 Tris-HCl buffer containing 50 mM NaCl. Working solution of substrate was prepared in 0.15 M pH 5.0 acetate buffer containing 100 mM NaCl, with an aliquot of 2 % by volume of
5 final buffer of 1-methyl-2-pyrrolidone used for initial dissolution of the substrate. Deionized water was used to dissolve buffer components. Reaction volume in each well was 224 μ l; concentration of elastase was 0.87 units/ml, and substrate, 363 μ M.

Enzymatic activity in cleaving the substrate was indicated by a development of yellow color measured as an increase in absorbance at 410 nm wavelength. The mean of maximum rate
10 of absorbance increase in negative control wells was considered as 100% of enzyme activity. IC₅₀ was calculated as concentration of test article in the well which reduced the elastase activity to 50%. Lower IC₅₀ values indicate higher potency and a degree of efficacy.

Inhibition of Kallikrein 5

Kallikrein 5 (KLK5), also known as *stratum corneum* tryptic enzyme, is a trypsin-like
15 serine protease. Recent *in vitro* and *in vivo* evidence implicates increased levels of KLK5 in augmented inflammatory response such as rosacea (Two AM, Del Rosso JQ, Kallikrein 5-mediated inflammation in rosacea: clinically relevant correlations with acute and chronic manifestations in rosacea and how individual treatments may provide therapeutic benefit. J Clin Aesthet Dermatol. 2014 Jan; 7(1): 20-5) and in induction of atopic dermatitis-like lesions (Briot
20 A. et al., Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med. 2009 May 11;206(5):1135-47). Normal human adult epidermal keratinocytes (HEK) were cultured as described above for the cytotoxicity evaluation. After incubation with test articles or controls for 16 hours, HEK cell culture supernatants were collected. KLK5 was quantified using a human
25 KLK5 immunoassay Quantikine ELISA kit (Catalog # DKK500, produced by R&D Systems, Minneapolis, MN). The changes of KLK5 concentrations between test articles and vehicle controls were calculated and compared. IC₅₀ (concentration of test article necessary to reduce KLK5 levels to 50% compared to samples from untreated cells) values were calculated by sigmoidal curve fitting with SigmaPlot 10.0 (Systat Software). Lower IC₅₀ values indicate higher
30 potency and a degree of efficacy.

Inhibition of IL-6 and/or IL-8 Induced by SDS

Normal human adult epidermal keratinocytes (HEK) were cultured as described above for the cytotoxicity evaluation. The cells were then incubated with test articles and/or controls for 16 hours. Presence of sodium dodecyl sulfate (SDS) in cell cultivation medium at specific concentrations was used for induction of chemokines and cytokines. IL-8 was induced by 6
5 $\mu\text{g}/\text{mL}$ SDS, IL-6 by 12.5 $\mu\text{g}/\text{mL}$ SDS. After incubation, HEK cell supernatants were collected. Quantikine® ELISA kits (R&D Systems Inc, Minneapolis, MN) were used to quantify these interleukins in the supernatants. IL-8 was quantified by Human CXCL/IL-8 Immunoassay kit (Catalog # D8000C), and IL-6 was quantified by Human IL-6 Immunoassay kit (Catalog # D6050). IC₅₀ (concentration of test article necessary to reduce interleukin levels to 50%, with
10 samples from untreated cells considered as 0% and samples treated solely with respective inducing quantity of SDS as 100%) values were calculated by sigmoidal curve fitting with SigmaPlot 10.0 (Systat Software). Lower IC₅₀ values indicate higher potency and a degree of efficacy.

15 Inhibition of IL-6 and/or IL-8 and/or PGE2 Induced by Full-Spectrum Sunlight from Artificial Source

Normal human adult epidermal keratinocytes (HEK) were cultured as described above for the cytotoxicity evaluation. The cells were washed once, and M154 was replaced with PBS. Both the washing and the replacement were done with PBS to remove light-absorbing components of M154. The 96-well plate containing HEK was then covered with UV-transparent
20 1 mm quartz sheet, placed on white underlay atop controlled Peltier-cooled surface maintaining room temperature, and irradiated with a dose of 20 J/cm² of artificially produced full spectrum sunlight at dose rate of about 1100 W/m², as measured via pyranometer through same quartz cover. PBS was then removed and replaced with M154, and cells were incubated with test articles and/or controls for 16 hours. Identical manipulations, with exception of presence of
25 sunlight, were carried out with HEK serving as unstressed controls. Irradiation equipment was obtained from Solar Light Company, Glenside, PA and included Solar Simulator LS1000-6R-002 in Airmass 1.5 configuration using plain mirror; XPS1000 precision current source, and PMA2144 Pyranometer. After incubation, HEK cell supernatants were collected. Quantikine® ELISA kits (R&D Systems Inc, Minneapolis, MN) were used to quantify interleukins in the
30 supernatants. IL-8 was quantified by Human CXCL/IL-8 Immunoassay kit (Catalog # D8000C), IL-6 was quantified by Human IL-6 Immunoassay kit (Catalog # D6050); and PGE2 was quantified using Parameter™ Prostaglandin E₂ Assay (Catalog # KGE004B). IC₅₀ (concentration of test article necessary to reduce interleukin or prostaglandin levels to 50%, with samples from non-irradiated cells considered as 0% and from irradiated cells considered as 100%) values were

calculated by sigmoidal curve fitting with SigmaPlot 10.0 (Systat Software). Lower IC₅₀ values indicate higher potency and a degree of efficacy.

Table 7 summarizes the results of evaluating inhibition of IL8 and PGE2 activity induced by full-spectrum sunlight from an artificial source and cytotoxicity (LDH/microscopy).

5

Table 7

Material	IL8 / full spectrum sun induction	PGE2 / full spectrum sun induction	Cytotoxicity (LDH/microscopy)
Whole Fruit Extract, Lot 0841	Some inhibition at low concentrations (~25% inhibition at 0.01%)	Inhibits at low concentrations, IC ₅₀ 0.01%	Cytotoxic at 0.1% and above
Fruit Peel Extract, Lot 0837	Inhibition at low concentrations (estimated IC ₅₀ 0.012%, max inhibition 66% at 0.05%)	Inhibits at low concentrations, IC ₅₀ 0.04%	No cytotoxicity at 0.1%
Fruit Peel Serum Fraction, Lot 1082	No significant inhibition	IC ₅₀ between 0.003-0.03%. Maximum inhibition 70% at 0.001%	No cytotoxicity at 0.1%
Whole Fruit Serum Fraction, Lot 0785	No significant inhibition	Maximum inhibition 40% at 0.01%	No cytotoxicity at 0.1%
Fruit Flesh + Fruit Seed Serum Fraction, Lot 1083	No significant inhibition	Non-significant inhibition at 0.01-0.02%	No cytotoxicity at 0.1%

Table 8 summarizes the results of evaluating inhibition of IL8 induced by SDS; KLK5 inhibition; IL18 inhibition; trypsin inhibition; elastase inhibition; and cytotoxicity.

Table 8

Material	IL8 inhibition (SDS)	KLK5	IL18	Cytotoxicity (LDH/microscopy)	Trypsin Inhibition	Elastase Inhibition
Achachariu (<i>Garcinia humilis</i>) Fruit Peel Serum Fraction, Lot 0822	Not tested	IC ₅₀ 0.18%	Maximum 1.46 fold (benchmark sensitizer 7.8 fold)	No cytotoxicity at 0.1%	IC ₅₀ 0.37%	IC ₅₀ 0.26%
Achachariu (<i>Garcinia humilis</i>) Whole Fruit Serum	About 65% inhibition at 0.1%	IC ₅₀ 0.2%	Maximum 1.8 fold (benchmark sensitizer 7.8 fold)	No cytotoxicity at 0.1%	IC ₅₀ 0.32%	IC ₅₀ 0.28%

Material	IL8 inhibition (SDS)	KLK5	IL18	Cytotoxicity (LDH/microscopy)	Trypsin Inhibition	Elastase Inhibition
Fraction, Lot 0786						

In summary, biological activity results suggest that preparations of achachariu: (i) are not skin sensitizers; (ii) are not cytotoxic at selected concentrations that could be relevant to their concentrations in finished product formulation; and (iii) potential usefulness for mitigating signs of skin aging caused by inflammation and related process (e.g., those triggered by stresses to the skin, including environmental stress such as full-spectrum sun exposure). More specifically, the test results suggested the following: (i) against PGE2, achachariu whole fruit extract is slightly more effective than fruit peel extract; (ii) against PGE2, achachariu fruit peel serum fraction is more effective than whole fruit serum fraction, which is tentatively better than fruit flesh+ fruit seed serum fraction; and (iii) achachariu whole fruit serum fraction is effective for inhibiting SDS-induced IL-8 activity, but not against sun-induced IL8, which is surprising. Also surprising was: (i) the potent inhibition demonstrated by fruit peel extract against sun-induced IL8 and fruit peel serum fraction against sun-induced PGE2; (ii) the lack of any notable activity by fruit flesh + fruit seed serum fraction; (iii) fruit peel serum fraction and whole fruit serum fraction are more cytotoxic than fruit flesh + fruit seed serum fraction; and (iv) whole fruit extract is more cytotoxic than fruit peel extract.

Anti-Oxidant Response Element Activation

The ARE is the so-called “master switch” believed to control the antioxidant defense system of most cells. When the ARE is activated in response to oxidative stress, the corresponding genes signal the cell to begin producing reduction/oxidation regulators and/or reactive oxygen species (“ROS”) quenching proteins and enzymes. ROS are highly reactive molecules formed naturally within cells as a natural byproduct of the normal metabolism of oxygen and play a role in cell signaling and homeostasis. However, when a cell is exposed to a stressor such as heat or UV radiation, ROS levels can increase, and in some instances dramatically. As the damage caused by ROS accumulates over time, it causes more and more oxidative stress at the cellular level that ultimately may lead to tissue damage and/or organ dysfunction. Thus, without being limited by theory, it is believed that if achachariu can demonstrate the ability to activate the ARE, then applying an effective amount of achachariu to keratinous tissue may help fight cellular damage associated with oxidative stress.

ARE activation was quantitated using the ARE-32 reporter cell line available from CXR-Biosciences as described below. ARE-32 is a stable MCF7 cell line containing pGL8x-ARE (8 copies of the rat GST ARE linked to the luciferase gene) and pCDNA3.1, which contains the neomycin selectable marker. Selection was performed in the presence of G418 and resistant clones were isolated. Clones were screened for induction of luciferase in response to tBHQ.

The ARE-32 cells are maintained routinely in Dulbecco's Modified Eagle Medium (phenol red free) ("DMEM") containing: 10% fetal bovine serum ("FBS"), 50 units/ml penicillin & 50 µg/ml streptomycin, 0.8 mg/ml G418. Cells are subcultured every 3-4 days. If needed, cells can be frozen in medium that contains 90% FBS and 10% DMSO.

10 ARE Method

In a 96 well-plate, 1×10^4 cells/well are seeded in 100 µl DMEM containing 50 units/ml penicillin, 50 µg/ml streptomycin, 0.8 mg/ml G418 and 10% FBS. Next, the cells are incubated at 37° C in a 5% CO₂ incubator for 24 hrs, and then the medium is replaced with 100 µl fresh media. The test samples are treated with achachariu serum fractions at the concentration listed in Table 11 (1 ul per well), the positive control is 25 uM TBHQ. (10 mM tBHQ of stock solution freshly prepared in DMSO). 100 ul of media is added after treatment for a final assay volume of 200 uL. The cells are incubated at 37° C in CO₂ incubator for another 24 hrs. The test samples are then assayed for luciferase activity with Steady-glo™ brand assay system according to the manufacturer's instruction.

20 The results of the test are summarized in Table 9. At concentrations of 0.167% to 1.5%, both the whole fruit and peel serum fractions appear to provide more ARE activation than than the control. The whole fruit also demonstrated a directional increase at 0.056% versus the control.

Table 9 – ARE Activation

v/v% achachariu	Whole fruit ¹ % increase vs control	p-value vs. control	Peel ² % increase vs control	p-value vs. control
1.5	929	0.000087	1133	0.000046
0.5	489	0.0023	614	0.00086
0.167	197	0.0076	209	0.0043
0.056	134	.0.091	113	0.67
0.0185	103	0.96	92	0.79
0.006173	112	0.83	99	0.99
0.002058	93	0.89	92	0.94
0.000686	120	0.78	93	0.94

25 1. Recentia® GH from AkzoNobel

2. Recentia[®] GH-P from AkzoNobel

Melanin Synthesis Inhibition – B16 Assay

Overproduction of melanin is generally associated with a variety of skin pigmentation conditions (e.g., age spots, vitiligo, solar lentigines, and melasma). Thus, without being limited by theory, it is believed that if achachariu can demonstrate the ability to inhibit melanin production, then applying an effective amount of achachariu to skin may help improve the appearance of skin pigmentation conditions.

A commercially available B16-F1 mouse melanoma cell line from American Tissue Culture Collection, Virginia, USA was employed in a conventional melanin synthesis inhibition assay. The cell culture medium used in the assay is 500 mL of Dulbecco's Modified Eagle's Medium ("DMEM"), 50 mL Fetal Bovine Serum ("FBS"), and 5 mL of penicillin-streptomycin liquid. B16-F1 cells that are cultured in this medium and grown to greater than 90% confluency will synthesize melanin. While not intending to be bound by theory, it is hypothesized that melanin synthesis is stimulated by the culture medium and/or stress induced by growth to a high confluency. The DMEM and FBS can be obtained from American Tissue Culture Collection and the penicillin-streptomycin liquid can be obtained from Invitrogen, Inc., California, USA. Equipment used in the assay include a CO₂ incubator (e.g., a Forma Series Model 3110 by Thermo Scientific, Massachusetts, USA or equivalent); a Hemocytometer (e.g., Bright Line model by Hauser Scientific, Pennsylvania, USA or equivalent); and a UV-Visible Spectrum Plate Reader (e.g., SpectraMax250 from Molecular Devices, California, USA or equivalent).

Day 0: To begin the assay, the cell culture medium is heated to 37 °C and 29 mL of the medium is placed into a T-150 flask. Approximately 1×10^6 of B16-F1 passage 1 mouse cells are added to the T-150 flask and incubated for 3 days at 37 °C, 5% CO₂, 90% relative humidity, until ~80% confluency.

Day 3: The cells from the T-150 flask are trypsinized, and the number of cells is determined using the Hemocytometer. Initiate a 96 well plate with 2,500 cells per well in 100 µL of cell culture medium. Incubate the plate at 37°C, 5% CO₂, 90% relative humidity for 2 days until at least 20% to 40% confluent.

Day 5: Remove the cell culture medium from the plate and replace with fresh culture medium (100 uL per well). Add 1 uL of test compound diluted in a water solvent. Multiple dilution ratios may be tested in order to generate a dose response curve, wherein preferably three wells are treated with each dilution ratio. Positive and negative controls may include wells

having the cell culture medium, B16-F1 cells, and the solvent (negative control), and wells comprising the cell culture medium, B16-F1 cells and and a known melanin inhibitor (e.g., deoxyarbutin or kojic acid).

Day 7: Cells should have greater than ~90% confluency. If not, this data point is not used. Add 100 uL of a 0.75% sodium hydroxide solution to each well. Read the 96-well plate using the UV-Vis Plate Reader at 410 nm to optically measure the amount of melanin produced between wells that are treated with the fava bean extract and control wells that are not. Wells in which melanin is produced appear brownish in color. Wells in which little melanin is produced appear clear to light purple in color. Percentage of melanin synthesis inhibition is calculated by the following equation:

$$\frac{100 - [\text{OD410 Test Compound} - \text{OD410 Control \#2}] \times 100}{(\text{OD410 Control \#1} - \text{OD410 Control \#2})}$$

Where OD410 is the Optical Density at 410 nm as measured by the UV-Vis Spectrum Plate Reader.

When Control #3 is used, the formula for percentage melanin synthesis inhibition is:

$$\frac{100 - [\text{OD410 Test Compound} - \text{OD410 Control \#3}] \times 100}{(\text{OD410 Control \#1} - \text{OD410 Control \#2})}$$

The concentration of test agent needed to provide the IC 50 is recorded.

The results of the test are summarized in Table 10, which shows that achachariu inhibits melanin synthesis, and thus is expected to provide a skin lightening benefit.

20

Table 10 – Melanin Synthesis Inhibition

B16 (IC 50)	
Composition	Concentration Needed for IC 50 (v/v%)
Achachariu ¹ (whole fruit)	0.19
Achachariu ² (peel only)	0.19

1. Recentia[®] GH from AkzoNobel
2. Recentia[®] GH-P from AkzoNobel

Lipogenesis inhibition

This example demonstrates the ability of achachariu to inhibit lipogenesis in human pre-adipocytes. Lipogeneis involves the synthesis of commonly known lipids such as fatty acids and triglycerides, and is one of primary ways mammals store energy. However, lipogenesis also

25

involves the synthesis of lipids such as sebum. Sebum is a lipid produced by sebocytes, which are a type of skin cell found primarily in the sebaceous glands of mammalian skin. Sebum is produced by the body to lubricate and waterproof the skin and hair of mammals. However, overproduction of sebum can result in oily appearing skin and/or skin that appears to have poor texture. Thus, without being limited by theory, it is believed that if achachariu can demonstrate the ability to inhibit lipogenesis, then applying an effective amount of achachariu to keratinous tissue may help regulate conditions associated with sebum overproduction.

Method

Human pre-adipocytes were selected for use in this example. Because of the known difficulty associated with culturing and testing sebocytes, pre-adipocytes are commonly used as a surrogate for sebocytes to determine the potential of a test agent to inhibit sebum production.

Human subcutaneous pre-adipocytes purchased from Zen-Bio, Inc (Cat. # SP-F-SL) were cultured in PM-1 media (available from Zen-Bio, Inc as Cat# PM-1 (plus 5ng/ml EGF)) to 80 – 90% confluency. The cells were transferred to 96-well clear bottom white plates to provide approximately 40,625 cells/cm² in the well (~12,500 cells) and 150 µl of PM-1 media per well, and then cultured for 24 – 48 hours in a 5% CO₂ incubator at 37 °C. The PM-1 media was then replaced with differentiation medium (Zen-Bio, Inc. Cat# DM-1), and the cells were incubated for another 6 days. After incubating in the differentiation medium, 90 µl of the differentiation medium was carefully replaced with 140 µl of human subcutaneous adipocyte medium ((Zen-Bio, Inc. Cat# AM-1). Care was taken not to touch or disturb the cells at the bottom of the well. 2 µl of achachariu (Recentia[®] GH-P for AkzoNoble) or control composition (100 µM Genistein (Cat# G6649) from Sigma) was added to each well daily for 9 days (total incubation of 15 days). On Day 15, 5 µL of AdipoRed reagent (Lonza; Cat. Number: PT-7009) was slowly added directly to cells in the treatment medium, and the plate was gently mixed after each row addition. The plate was incubated for 15 minutes at room temperature. Lipogenesis was quantitated using an EnVision[®] brand Fluorescent spectrophotometer Plate Reader according to the AdipoRed protocol. The plates were scanned from the bottom using the 451 mirror and (excitation 485 nm; emission 535) filter. Each well was scanned in a Z pattern (7 reads across from left to right, 7 reads diagonally from right to left and 7 reads across from left to right for a total of 21 end points).

Percent inhibition was calculated as:
$$\frac{\text{Average Control RFU} - \text{Sample RFU}}{\text{Average Control RFU}} \times 100$$

The cells were assayed and normalized to the control by using a FluoReporter[®] Blue Fluorometric brand dsDNA Quantitation Kit. Immediately after the screen the AdipoRed

containing cell media was gently aspirated, cells were rinsed with 100ul 1X PBS taking care not to dislodge them from the bottom and 100ul distilled water was added/well. The plates were frozen at -80°C to lyse the cells and assayed according to the kit instructions at a later date.

The results of the test are summarized in Table 11, which shows that achachariu inhibits lipogenesis, and thus is expected to help regulate conditions associated with the overproduction of sebum.

Table 11 – Lipogenesis Inhibition

Compostion	IC 50 w/v%
Recentia® GH-P (achachariu peel)	0.4%
Recentia® GH (achachariu whole fruit)	0.5%

Inhibiting the Cell's Inflammation Response to a Stressor - NF-kappa-beta ("NF-kB") assay.

NF-kB (i.e., nuclear factor kappa-light-chain-enhancer of activated B cells) is a protein complex that belongs to the category of "rapid-acting" primary transcription factors (i.e., transcription factors that are present in cells in an inactive state and do not require new protein synthesis in order to become activated), which allows NF-kB to be a first responder to harmful cellular stimuli such as ROS and other stressors. NF-kB is found in almost all animal cell types and is known to be involved in the cellular inflammation pathway. Cellular inflammation is associated with a variety of skin conditions, and thus inhibiting NF-kB activation vis-à-vis cellular inflammation with an effective amount of achachariu may help treat these types of skin conditions.

Method

CellSensor™ NF-kB *-bla* HEK 293T cells (Invitrogen, Cat. # K1165) were plated in assay medium (DMEM with high glucose (Gibco, Cat. #11965) plus 10% dialyzed FBS). The cells were cultured and seeded at 10,000/well in 96-well plates (black-sided Poly-D-Lysine coated plates, BD # 356692), and then incubated at 37 °C and 95% RH for the 72 hours prior to testing. Recombinant human TNF α (available from R&D systems) was used to stimulate NF-kB activation in the cells. Fisetin (3, 7, 3', 4'-tetrahydroxyflavone) was used to inhibit stimulation of the cells by TNF α . A ToxBLAzer™ DualScreen brand screening kit (Invitrogen, Cat. #K1138) was used as the fluorescent substrate according to the manufacturer's instructions.

The following controls were run on each plate in the assay:

High control (Stimulated) = cells + TNF α + 1% DMSO

Blank (Unstimulated) = cells + 1% DMSO

Standard (Positive control inhibitor) = cells + TNF α + Fisetin + 1% DMSO

Negative Control (no cells) = assay medium

5 NF- κ B % inhibition is calculated as: $\frac{\text{High Control} - \text{Sample}}{\text{High Control} - \text{Blank}} \times 100$

The results of this test are summarized in Table 12 below. As illustrated in Table 12, the achachariu whole fruit serum fractions and achachariu peel serum fractions provided an IC 50 for NF- κ B inhibition of 2%. Thus, applying an effective amount of achachariu to a target portion of keratinous tissue may help regulate conditions related to cellular inflammation.

10 Table 12

Compostion	IC 50 (v/v%)	Cytotoxicity
Recentia® GH-P (Achachariu Peel only)	2%	None observed
Recentia® GH (Achachariu whole fruit)	2%	None observed

Inhibiting the Cell’s Inflammation Response to a Stressor - Prostaglandin E2 (“PGE2”) assay.

PGE2 is a hormone-like substance that is known to participate in modulation of inflammation. Cellular inflammation is associated with a variety of skin conditions, and thus
 15 inhibiting PGE2 activation vis-à-vis cellular inflammation may help treat these types of skin conditions.

Method

Tert keratinocytes (“tKC”) were plated at 40,000 cells/well into 24-well plates in 1 ml/well volume. EpiLife Medium (Life Technologies cat # MEPICFPRF500) supplemented with
 20 keratinocyte growth supplement (Life technologies cat #S-001-5) was used as the assay media. The cells were grown to confluence/near confluence, and then subjected to 15 mJ/cm² UVB-stress. The test compositions (achachariu and vehicle control) (diluted 1:1000) were added, and the plates were incubated for 18-24 hours. The supernatant was removed from each well, and the cells were rinsed with 2 ml/well medium (without supplements). A Cell Titer-Glo assay
 25 (measures ATP activity) was conducted on the cells for normalization. The supernatant was tested in a PGE2 assay (Prostaglandin E2 Assay kit from Cisbio Bioassays cat# 62P2APEB) according to the manufacturer’s instructions. The PGE2 results were normalized to ATP activity.

The results of the PGE2 assay are summarized in Table 13. The achachariu whole fruit serum fraction and achachariu peel serum fractions both demonstrated the ability to inhibit release of PGE2 from keratinocytes exposed to 15 mJ/cm2 UVB radiation, which illustrates anti-inflammatory activity of achachariu. Thus, a personal care composition comprising achachariu may be useful for regulating a skin condition related to cellular inflammation.

Table 13

Test	PGE2 Release (% of vehicle control)	StDev
Recentia® GH-P Achachariu peel	28%	8.20%
Recentia® GH (Achachariu whole fruit)	52%	11.40%
Vehicle control	98%	13.20%

The dimensions and values disclosed herein are not to be understood as being strictly limited to the exact numerical values recited. Instead, unless otherwise specified, each such dimension is intended to mean both the recited value and a functionally equivalent range surrounding that value. For example, a dimension disclosed as “40 mm” is intended to mean “about 40 mm”.

All documents cited in the Detailed Description of the Invention are, in relevant part, incorporated herein by reference; the citation of any document is not to be construed as an admission that it is prior art with respect to the present invention. To the extent that any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition assigned to that term in this document shall govern.

Whereas particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.

CLAIMS

What is claimed is:

1. A method of regulating a skin condition, comprising:
 - a. identifying a target portion of skin in need of treatment or where treatment is desired; and
 - b. applying a skin care composition comprising an effective amount of achachariu serum fraction to the target portion of skin during a treatment period, wherein the treatment period is sufficient for the achachariu serum fraction to provide a skin care benefit.
2. The method of claim 1, wherein the achachariu serum fraction is present in the skin care composition at an amount of about 0.01% to about 15%.
3. The method of claim 1 or 2, wherein the achachariu serum fraction is obtained from a peel of an achachariu fruit.
4. The method of any one of claims 1 to 3, wherein the achachariu serum fraction has a dry matter content of less than 25%.
5. The method of any one of claims 1 to 4, wherein the achachariu serum fraction is substantially free of at least one of benzophenone and protein.
6. The method of any one of claims 1 to 5, wherein the skin care composition further comprises about 20% to about 99.99% of a dermatologically acceptable carrier.
7. The method of any one of claims 1 to 6, wherein the skin care composition further comprises at least one additional active selected from vitamins, minerals, peptides, sugar amines, anti-oxidants, preservatives, anti-inflammatory agents, moisturizing agents, skin lightening agents, particles, anti-wrinkle actives, anti-atrophy actives, N-acyl amino acid compounds, and combinations of these.
8. The method of any one of claims 1 to 7, wherein the skin care composition comprises a preservative selected from pentylene glycol, tetrasodium EDTA, sodium metabisulfite, potassium sorbate, sodium benzoate.
9. The method of any one of claims 1 to 8, wherein the skin care benefit is selected from an anti-inflammatory benefit, an anti-aging benefit, an anti-oxidant benefit, and a lipogenesis inhibition benefit.

10. The method of claim 1, wherein the skin care composition comprises an effective amount of an achachariu extract.
11. The method of claim 10, wherein the personal care composition comprises an effective amount of the achachariu extract instead of the achachariu serum fraction.
12. The method of claim 10 or 11, wherein the achachariu extract is obtained from a peel of an achachariu fruit.
13. The method of any one of claims 10 to 12, wherein the achachariu extract comprises polar compounds extracted from achachariu plant material using a polar solvent.
14. The method of any one of claims 10 to 12, wherein the achachariu extract comprises non-polar compounds extracted from achachariu plant material using a non-polar solvent.
15. The method of any one of claims 10 to 14, wherein the achachariu extract is substantially free of at least one of benzophenone and protein.

1/6




Fig. 1




Fig. 2




Fig. 3A





Fig. 3B



- GH 0837, ~100mcl quartz, 0.1%, minus DiPG
- GH 0838, ~100mcl quartz, 0.1%, minus DiPG
- GH 0841, ~100mcl quartz, 0.1%, minus DiPG
- GH 0842, ~100mcl quartz, 0.1%, minus DiPG

Wavelength, nm

Fig. 4A




Fig. 4B

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2016/064888

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61Q19/00 A61Q19/02 A61Q19/08 A61K8/97
ADD.
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
A61Q A61K
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, BIOSIS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Anonymous: "AmyG Cosmetics (Seek Beauty) - Guys Family Pharmacy", 14 August 2015 (2015-08-14), XP055339309, Retrieved from the Internet: URL:http://web.archive.org/web/20150814044017/https://www.guysfamilypharmacy.com/amy-g-cosmetics-seek-beauty/ [retrieved on 2017-01-26] products 591 and 593; page 1 ----- -/--	1-15

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent but published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 9 February 2017	Date of mailing of the international search report 20/02/2017
---	---

Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Authorized officer Ovens, Annabel
--	---

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2016/064888

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Anonymous: "Seek Beauty: An Interview with Amy Greeson If the Muumuu Fits", 10 June 2015 (2015-06-10), XP055339286, Retrieved from the Internet: URL:http://www.ifthemuumuufits.com/seek-beauty-an-interview-with-amy-greeson/ [retrieved on 2017-01-26] the whole document	1-15
A	L N B Mariano ET AL: "Composição química de Garcinia achachairu Rusby (CLUSIACEAE)", 22o Simpósio de Plantas Medicinai s, 31 December 2012 (2012-12-31), XP055339323, Retrieved from the Internet: URL:http://www.ufrgs.br/spmb2012/Trabalhos/3430_1337110179_Simpósio_BG2012.pdf [retrieved on 2017-01-26] the whole document	1-15
A	PETERSON MENEZES TERRAZAS ET AL: "Benzophenone guttiferone A from Garcinia achachairu Rusby (Clusiaceae) Presents Genotoxic Effects in Different Cells of Mice", PLOS ONE, vol. 8, no. 11, 8 November 2013 (2013-11-08), page e76485, XP055343240, DOI: 10.1371/journal.pone.0076485 the whole document	1-15
A	BR 1020 1302 9865 A2 (UNIV FED RURAL DE PERNAMBUCO [BR]) 20 October 2015 (2015-10-20) page 7, line 27 - page 8, line 4	1-15
A	WO 2014/076055 A1 (AKZO NOBEL CHEMICALS INT BV [NL]) 22 May 2014 (2014-05-22) the whole document	1-15
A	US 2013/164323 A1 (RICHARDS JEANETTE ANTHEA [US] ET AL) 27 June 2013 (2013-06-27) cited in the application the whole document	1-15
A	US 2012/201768 A1 (SWANSON CHERI LYNN [US] ET AL) 9 August 2012 (2012-08-09) cited in the application the whole document	1-15
	-/--	

INTERNATIONAL SEARCH REPORT

International application No

PCT/US2016/064888

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 2008/206373 A1 (MILLIKIN CHERI LYNN [US] ET AL) 28 August 2008 (2008-08-28) cited in the application the whole document -----	1-15

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No PCT/US2016/064888

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
BR 102013029865 A2	20-10-2015	NONE	
WO 2014076055 A1	22-05-2014	AR 093497 A1	10-06-2015
		AU 2013346997 A1	09-04-2015
		CA 2890482 A1	22-05-2014
		CN 104768534 A	08-07-2015
		EP 2919757 A1	23-09-2015
		JP 2015536966 A	24-12-2015
		KR 20150083996 A	21-07-2015
		SG 11201503555R A	29-06-2015
		TW 201434492 A	16-09-2014
		US 2015258012 A1	17-09-2015
		WO 2014076055 A1	22-05-2014
US 2013164323 A1	27-06-2013	EP 2793847 A2	29-10-2014
		JP 5860166 B2	16-02-2016
		JP 2015502407 A	22-01-2015
		US 2013164323 A1	27-06-2013
		WO 2013096736 A2	27-06-2013
US 2012201768 A1	09-08-2012	CA 2810516 A1	15-03-2012
		CN 103096872 A	08-05-2013
		EP 2613763 A2	17-07-2013
		JP 5819966 B2	24-11-2015
		JP 2013537196 A	30-09-2013
		US 2012201768 A1	09-08-2012
		WO 2012033989 A2	15-03-2012
US 2008206373 A1	28-08-2008	CN 101621987 A	06-01-2010
		EP 2124877 A2	02-12-2009
		US 2008206373 A1	28-08-2008
		WO 2008104941 A2	04-09-2008